Clinical data | |
---|---|
Trade names | Livalo, Livazo, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a610018 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth (tablets) |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 60% |
Protein binding | 96% |
Metabolism | Liver (CYP2C9, minimally) |
Elimination half-life | 11 hours |
Excretion | Faeces |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.171.153 |
Chemical and physical data | |
Formula | C25H24FNO4 |
Molar mass | 421.468 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Pitavastatin (usually as a calcium salt) is a member of the blood cholesterol lowering medication class of statins.[1]
Like other statins, it is an inhibitor of HMG-CoA reductase, the enzyme that catalyses the first step of cholesterol synthesis.
It was patented in 1987 and approved for medical use in 2003.[2] It is available in Japan, South Korea and in India.[3] In the US, it received FDA approval in 2009.[4] Kowa Pharmaceuticals, a subsidiary of Kowa Company, is the owner of the American patent to pitavastatin.